Cerus is a biomedical products company focused on the field of blood safety, and dedicated solely to
safeguarding the world’s blood supply. The company develops and supplies vital technologies and
pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on
safe blood.
The INTERCEPT Blood System, our robust pathogen inactivation process, is designed to reduce the risk
of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria
and parasites that may be present in donated blood.
Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe,
Canada, the United States of America, the Commonwealth of Independent States, the Middle East and
selected countries in other regions around the world.
The INTERCEPT Blood System is the only pathogen reduction system with both CE mark and FDA
approval for platelets and plasma. The INTERCEPT red blood cell system is in late-stage clinical
development.
